Lanthanide MOF-based luminescent sensor arrays for the detection of castration-resistant prostate cancer curing drugs and biomarkers
Xinrui Wang, Karuppasamy Gopalsamy, Gilles Clavier, Guillaume Maurin, Bin Ding, Antoine Tissot, Christian Serre
Abstract
-MOF (MOF 3) has demonstrated good sensing performances for CRPC curing drugs in real human serum samples. Furthermore, the curing drug hydroxyflutamide has been combined with MOF 3, to construct a robust composite sensing platform MOF 3@hydroxyflutamide for highly efficient detection of CRPC biomarkers such as the androgen receptor (AR) and prostate-specific antigen (PSA). Finally, luminescence lifetime measurements, zeta potential measurements, and density functional theory (DFT) calculations were performed to gain insights into the sensing mechanism.
Topics & Concepts
Prostate cancerBimetallic stripLanthanideLuminescenceNanotechnologyMedicineMaterials scienceChemistryCancerInternal medicineMetalOptoelectronicsMetallurgyIonOrganic chemistryMetal-Organic Frameworks: Synthesis and ApplicationsLanthanide and Transition Metal ComplexesNanocluster Synthesis and Applications